TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Perioperative Chemotherapy in Gastric Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* cT1b-T4b (cT4b - invasion in diaphragm, parenchyma of liver, spleen, pancreas, abdominal wall, small bowel, colon, distal part of splenic artery)~* cN0-3~* M0~* Age: 18 - 80~* ECOG: 0 - 1~* Histological type: adenocarcinoma~* Differentiation grade: G0 - G4~* No previous surgery~* No previous chemotherapy~* No concomitant severe comorbidity~* Written informed consent~Exclusion Criteria:~* cT1a, cT4b (invasion in truncus, hepatic artery, proximal part of splenic artery)~* Presense of distant metastases~* ECOG: 2 - 5~* Age: \<18 and \>80~* Severe concomitant comorbidity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Perioperative XELOX chemotherapy (Type: ACTIVE_COMPARATOR): Oxaliplatin 130 mg/m2, d1 Capecitabine 1000 mg/m² two times per day (BID), d1-14, every 3 weeks (q3w) 4 cycles (12 weeks) pre-OP and 3 cycles (12 weeks) post-OP
- Perioperative FLOT chemotherapy (Type: EXPERIMENTAL): Docetaxel 50mg/m2, d1 5-FU 2600 mg/m², d1 Leucovorin 200 mg/m², d1 Oxaliplatin 85 mg/m², d1 every two weeks (q2w) 4 cycles (8 weeks) pre-OP and 4 cycles (8 weeks) post-OP

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cardiac Resynchronization Therapy (CRT) on Left Ventricular Assist Device (LVAD) Function

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* All patients who have undergone implantation of both a biventricular pacemaker and LVAD who are at least three months post-LVAD implantation and who receive routine follow-up care at the UC Davis / UC San Diego Adult Arrhythmia/ Device/ LVAD clinic.~* Potential enrollees have been directly identified by their existing medical providers in clinic, who are investigators in this study.~Exclusion Criteria:~* Any patients who do not present to their routine follow-up appointment at the time of this study.~* Any patients who have undergone LVAD placement less than three months prior to enrollment.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort (Type: EXPERIMENTAL): Pacemakers will be programmed to BiV pacing, left ventricular (LV) pacing, right ventricular (RV) pacing and no pacing for five minutes each. LVAD flow will be recorded every thirty seconds for five minutes with each setting. Once the interventions have been completed, all pacemakers will be returned to their original setting.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: The Relationship Between Neuropsychological Testing and MRI, PET and COBRE - Project 1: AIM 2 (GE-180)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Be enrolled in CNTN~2. Aged 55 to 90~3. Available study partners~4. Willing and able to participate in longitudinal follow-up study~5. For MCI patients, fit criteria based in Movement Disorders Task Force or NIA~Exclusion Criteria:~1. Significant neurological disorders other than AD or PD;~2. Unstable medical conditions~3. History of major psychiatric diseases~4. MRI evidence of infarction or other focal lesion or multiple lacunes~5. Clinically significant abnormalities in B12 or TSH~6. Identified as having a common polymorphism (rs6971) in the TSPO gene which has been shown to reduce binding affinity of tracers similar to GE180. This testing will be done as part of their CNTN participation.

- Gender: ALL
- Minimum Age: 55 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Alzheimer's Disease (Type: EXPERIMENTAL): Alzheimer's Disease~GE180 PET Scan
- Parkinson's Disease (Type: EXPERIMENTAL): Parkinson's Disease~GE180 PET Scan
- Control (Type: EXPERIMENTAL): Control Group~GE180 PET Scan
- Mild Cognitive Impairment (Type: EXPERIMENTAL): Mild Cognitive Impairment~GE180 PET Scan

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pegylated Interferon - α2b With SARSCoV- 2 (COVID-19)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Ability to comprehend and willingness to sign a written ICF for the study.~2. Male or non-pregnant females, ≥18 years of age at the time of enrolment.~3. Understands and agrees to comply with planned study procedures.~4. Agrees to the collection of pharyngeal swabs and blood sample as per protocol.~5. Has laboratory-confirmed SARS-CoV-2 infection as determined by PCR, or other commercial or public health assay in any specimen within one week~6. Patients with SpO2 \> 93% and respiratory rate \<30 breaths/min.~7. Illness of any duration, and at least one of the following:~   1. Radiographic infiltrates by imaging (chest x-ray)~  2. Clinical assessment (evidence of rales/crackles or other clinical symptoms on exam).~8. Women of childbearing potential must agree to use at least one primary form of contraception~Exclusion Criteria:~1. ALT/AST \>5 times the upper limit of normal.~2. Patients with respiratory rate \<20 breaths/min and normal SpO2 with confirmed SARS-CoV-2 infection as determined by PCR (Mild COVID-19 subjects).~3. Patients with respiratory rate ≥30 breaths/min and SpO2 at rest ≤93% (Severe COVID-19 subjects).~4. Stage ≥4 severe chronic kidney disease or requiring dialysis (i.e. eGFR \<30 mL/min/1.73 m2).~5. Pregnant or breast feeding.~6. Allergy to any study medication or usage of test drug during last 14 days prior to screening~7. Severe co-morbidity (e.g. uncontrolled hypertension and uncontrolled DM, systemic disease which affect the vital organs severity, immunocompromised patients etc.) as per investigator's assessment.~8. Comorbid condition like myocardial infarction or heart failure within 90 days of recruitment.~9. Prolong QT interval (\>450 ms).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pegylated Interferon-α2b + Standard of care (Type: EXPERIMENTAL): Test :- Pegylated Interferon-α2b + Standard of care (SOC)~Pegylated Interferon-α2b-Initial 1 mcg/kg will be administered on day 1. After safety evaluation of first dose, next dose (second dose) 1 mcg/kg on day 8 will be administered along with the recommended standard of care at the time of conduct of trial.
- Standard of Care (Type: ACTIVE_COMPARATOR): Control: Standard of care~Standard of care treatment will be provided as per regulatory recommendation and approval.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of the the ETView Double-lumen Tube

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* elective thoracic surgery with anticipated use of a DLT~Exclusion Criteria:~* left pneumonectomy or left lobectomy requiring an anastomosis on the left main bronchus~* proximal left bronchial lesion~* anatomical abnormality of the bronchial tree~* suspicion of difficult mask ventilation or intubation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EtView (Type: EXPERIMENTAL): Use of ETVew double-lumen tube

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Strongest Predictors of a Positive Outcome After Physiotherapy for Knee Osteoarthritis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Clinical and radiological osteoarthritis of the knee and referred to physiotherapists.~2. Symptomatic daily during the last month.~3. Symptomatic for more than one year.~4. Able to walk up and down a flight of 10 stairs with or without walking aids.~5. Able to walk 3 stairs up and down without walking aids.~6. Understand Norwegian orally and in writing.~7. Body mass index below 35.~Exclusion Criteria:~1. Neurological, rheumatic, orthopedic, or respiratory diagnosis, other than osteoarthritis of the knee which can negatively affect the walking ability, balance or pain.~2. Body mass index above or equal to 35.~3. Fracture of the femur or shank, or arthroscopic surgery in the osteoarthritic knee.~4. Chronic generalized pain (American College of Rheumatology Criteria, 2010).~5. Inability to understand Norwegian language.

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- knee osteoarthritis (Type: None): Patients with knee osteoarthritis after having started physical therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Optical Coherence Tomography for Screening and Diagnosis of Colorectal Precancerous and Malignant Polyps

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Undergoing standard of care colonoscopy for the evaluation of colonic polyps.~* At least 40 years of age.~* Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).~Exclusion Criteria:~* Pregnant and/or breastfeeding.~* Unable to tolerate sedation.

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Optical coherence tomography (OCT) probe (Type: EXPERIMENTAL): After consent, the endoscopist will perform a standard of care colonoscopy. If a polyp is found, then OCT will be used to image that polyp. Patients with polyps, regardless of number found, will have either one tubular adenoma (NICE type 2) imaged OR one hyperplastic polyp (NICE type 1) imaged. If no polyps are found, then one area of normal mucosa will be imaged. If on the rare chance a malignant appearing colonic tumor (NICE type 3) is found, this and no other polyps will be imaged with OCT.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Adaptive Cardiac Resynchronization Therapy Optimization at Rest and During Exercise (AdOPT CRT)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is age 18 or greater~* Subject is willing to sign and date the study Informed Consent form~* Subject has been implanted with a clinically indicated CRT-D device (Medtronic Vision 3D or Protecta models) for at least 1 month but less than 7 months from the date of study enrollment~Exclusion Criteria:~* Subject has a history of persistent or permanent AF for which pharmacological therapy and/or cardioversion have been unsuccessful or have not been attempted.~* Subject has atrial or ventricular tachyarrhythmias or frequent atrial or ventricular ectopy at the time of enrollment.~* Subject's resting heart rate at the time of enrollment exceeds 90 bpm.~* Subject had CRT system implanted for more than 7 months from the date of the study enrollment~* Subject has complete AV block.~* Subject had previous mechanical valve surgeries.~* Subject has congenital heart disease.~* Subject has contraindication for an exercise test.~* Subject is unable to perform a sub-maximal exercise test.~* It is not possible to acquire technically acceptable echocardiographic images.~* Subject has medical conditions that would limit study participation.~* Subject is pregnant (all women of child-bearing potential must undergo a pregnancy test within seven days prior to the study visit).~* Subject is enrolled in the Adaptive CRT study~* Subject is enrolled in concurrent studies which could confound the results of this study.~* Subject meets exclusion criteria required by local law

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- CRT pacing at rest and during exercise (Type: EXPERIMENTAL): Rest and sub-maximal exercise

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Effectiveness Study of the HERCULINK 14 Stent to Treat Renal Artery Disease

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of renal artery atherosclerosis; candidate for renal artery angioplasty and stenting; blood pressure \>160/90~Exclusion Criteria:~* Totally occluded renal artery on the opposite side; only one functioning kidney; target lesion is in a transplanted kidney; renal insufficiency

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Cone Beam and CT Scan for the Diagnosis of Otosclerosis (TACOS)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* CT scan indicated for the diagnosis and pre-operatice assessment of an otosclerosis~Exclusion Criteria:~* Pregnancy~* Breast feeding~* Patient under a legal protection procedure~* Patient denying to participate to the study~* Lack of affiliation to a social security system

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eligible patients for cone-beam (Type: EXPERIMENTAL): A cone-beam computed tomography will be offered to the patients undergoing a CT scan for the diagnosis and/or the pre-operative assessment of an otosclerosis, fulfilling the inclusion criterias and without any exclusion criteria.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Reduced Intensity Transplant in Medically Refractory Systemic Lupus Erythematosus (SLE) and Systemic Sclerosis (SSc)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diffuse Systemic Sclerosis and variants as per ACR criteria~* Medically refractory disease~* Adequate Organ Function - Pulmonary function~* Renal function, Cardiac function defined as:~* SGOT (AST) or SGPT (ALT) \<5 x upper limit of normal~* Diagnosis of SLE - Medically refractory disease~Exclusion Criteria:~* Karnofsky/Lansky \<60%

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Reduced Intensity Regimen for Refractory SLE (Type: EXPERIMENTAL): RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with medically refractory Systemic Lupus Erythematosus (SLE).
- Reduced Intensity Regimen for SSc (Type: EXPERIMENTAL): RI regimen of fludarabine/busulfan and Alemtuzumab (FBA) followed by AlloSCT in selected patients with Systemic Sclerosis (SSc).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: CIS001 Extension Study of Cyclosporine Inhalation Solution

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Enrollment in study CIS001~2. Written informed consent for CIS002~3. Use of an effective means of contraception by women of childbearing potential~Exclusion Criteria:~1. Any unresolved or irreversible CIS-related ongoing serious adverse event~2. Subjects who have developed newly emergent conditions, injuries, diagnoses, physical examination findings, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the subject at high risk of treatment complications~3. Subjects with suspected or documented allergy to propylene glycol and/or cyclosporine~4. Women who are pregnant, wishing to become pregnant, or unwilling to use appropriate birth control to avoid becoming pregnant~5. Women who are breastfeeding~6. Subjects unable to comply with all protocol requirements and follow-up procedures~7. Subjects who discontinued from CIS002 to participate in another clinical trial and have received any investigational treatment (other than CIS) within 14 days of titration visit 1/baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Inhaled cyclosporine (Type: OTHER): Extended access to inhaled cyclosporine for patients from treatment and control arms of Phase 3 study CIS001

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Initiating Transdermal Estradiol Therapy in Turner's Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 60 subjects will be recruited from participating Pediatric Endocrinology Clinics in the United States.~* Subjects will be 11.5-13.0 years of age and must have completed at least 6 months of GH therapy prior to the study.~* Subjects may not have had any estrogen prior to the study. All subjects must be breast stage 1 and euthyroid prior to the study~* Those on thyroid medication will continue the appropriate thyroid replacement therapy during the study.~Exclusion Criteria:~* On estrogen therapy, breast stage 2 or greater, not on GH for at least 6 months.

- Gender: FEMALE
- Minimum Age: 138 Months
- Maximum Age: 13 Years
- Healthy Volunteers: f

Study Arms:
- GH alone, Low dose E2 patch, Very Low-dose E2 patch (Type: EXPERIMENTAL): Group 1: Growth hormone alone, no E2. Group 2: Growth Hormone plus Estradiol patch dose A(14 mcg/d x 10 d) x 6 months then Estradiol patch dose B(25 mcg/d x 10 d) x 6 months.~Group 3: Growth Hormone plus Estradiol patch dose B(25 mcg/d x 10 d) x 6 months then Estradiol patch dose C(25 mcg/d x 3 w) x 6 months.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues